KalVista wins grant for DME treatment

KalVista Pharmaceuticals has received a £2.4 million grant to accelerate development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema.

Related Videos
View All
Related Content
© 2023 MJH Life Sciences

All rights reserved.